News

New Haven, CT, December 20, 2018 – Kleo Pharmaceuticals Inc., a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics, … [Read more...] about Kleo Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco

New Haven, CT, November 13, 2018 – Kleo Pharmaceuticals Inc., an immuno-oncology company pioneering a new class of bi-specific, small molecule compounds designed to emulate or enhance biologics … [Read more...] about Kleo Pharmaceuticals Secures $21 Million to Advance Novel Small Molecule Cancer Immunotherapies

NEW HAVEN, Conn., April 5, 2018 /PRNewswire/ -- Kleo Pharmaceuticals, a biopharmaceutical company developing innovative small molecule immunotherapies, announced today that CEO Doug Manion, M.D. FRCP … [Read more...] about Kleo Pharmaceuticals Selected to Present at Biotech Innovation Conference

New Haven, CT—April 2, 2018 Kleo Pharmaceuticals Inc., a biotechnology company pioneering a new class of immunotherapies utilizing small molecules to activate an individual’s own immune system to … [Read more...] about Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer

New Haven, CT – July 18, 2017 PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) and Kleo Pharmaceuticals Inc., a New Haven-based company using its … [Read more...] about PeptiDream and Kleo Pharmaceuticals Announce Collaboration Agreement to Develop Novel Immunotherapies for Oncology